Back to companies

IPCA Laboratories Ltd: Premium Databases

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

IPCA Laboratories Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of IPCA Laboratories Insights data

Headline Published Journalists
Showing 3 of 3 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 26 Aug 2021 Lorem
Small Pharma considers RFP submissions for CROs for Phase IIb major depressive disorder trial by YE; Onyx Scientific is CMO for Phase I/IIa, exec says- CORRECTION 26 Aug 2021 William Newton
Neuronascent seeks USD 3m Series A for expanded Phase Ia Alzheimer’s trial in 2016; signs NDA for Parkinson’s asset – CEO 12 May 2016 Alissa Fleck
Neuronascent seeks USD 2m for Phase I Alzheimer’s trial - CSO 23 Apr 2014 Casey McDonald
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Gain a 360-degree view of IPCA Laboratories Ltd and make more informed decisions for your business
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer